Literature DB >> 35441778

Late-onset Proteus syndrome with cerebriform connective tissue nevus and subsequent development of intraductal papilloma.

Emily W Modlin1, Anne M Slavotinek2, Thomas N Darling3, Stanley Lipkowitz4, Frederic G Barr5, Pamela N Munster6, Leslie G Biesecker1, Christopher A Ours1.   

Abstract

Proteus syndrome (PS) is a rare segmental overgrowth disorder caused by a mosaic activating variant in AKT1. The features of PS are often not present at birth but develop during the first few years of life. We describe a 55-year-old female, whose first symptom of overgrowth, a cerebriform connective tissue nevus, occurred at 19 years of age. We report the identification of the AKT1 c.49G > A p.(Glu17Lys) variant in this progressive lesion, the bony overgrowth, and recurrence after surgical intervention. In the sixth decade of life, this individual developed intraductal papillomas within her right breast which were confirmed to contain the same activating AKT1 variant as the connective tissue nevus. While similar neoplasms have been described in an individual with Proteus syndrome, none has been evaluated for the presence of the AKT1 variant. The tumor also contained two likely pathogenic variants in PIK3R1, c.1392_1403dupTAGATTATATGA p.(Asp464_Tyr467dup) and c.1728_1730delGAG p.(Arg577del). The finding of additional genetic variation putatively affecting the PI3K/AKT pathway in the neoplastic tissue may provide preliminary evidence of a molecular mechanism for tumorigenesis in PS. The late onset of symptoms and molecular characterization of the breast tumor expand the clinical spectrum of this rare disorder.
© 2022 Wiley Periodicals LLC. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.

Entities:  

Keywords:  Proteus syndrome; connective tissue nevus; intraductal papilloma; overgrowth

Mesh:

Substances:

Year:  2022        PMID: 35441778      PMCID: PMC9519031          DOI: 10.1002/ajmg.a.62761

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.578


  26 in total

Review 1.  The challenges of Proteus syndrome: diagnosis and management.

Authors:  Leslie Biesecker
Journal:  Eur J Hum Genet       Date:  2006-08-02       Impact factor: 4.246

2.  Morphological characterization of the breast in Proteus syndrome complicated by ductal carcinoma in situ.

Authors:  Jabed Iqbal; Gary He; Leslie G Biesecker; Peter Rosen; Paul H Duray; Douglas Schwartzentruber; Mansor Beg; Ellen Kahn
Journal:  Ann Clin Lab Sci       Date:  2006       Impact factor: 1.256

3.  Mild and delayed-onset Proteus syndrome.

Authors:  Suju Luo; Yiguo Feng; Yan Zheng; Zhenhui Peng; Junmin Wang; Guorong Wang
Journal:  Eur J Dermatol       Date:  2007-03-02       Impact factor: 3.328

4.  Somatic AKT1 mutations cause meningiomas colocalizing with a characteristic pattern of cranial hyperostosis.

Authors:  Kim M Keppler-Noreuil; Eva H Baker; Julie C Sapp; Marjorie J Lindhurst; Leslie G Biesecker
Journal:  Am J Med Genet A       Date:  2016-08-23       Impact factor: 2.802

5.  Progressive overgrowth of the cerebriform connective tissue nevus in patients with Proteus syndrome.

Authors:  Thomas M Beachkofsky; Julie C Sapp; Leslie G Biesecker; Thomas N Darling
Journal:  J Am Acad Dermatol       Date:  2010-08-14       Impact factor: 11.527

Review 6.  Genital tract tumors in Proteus syndrome: report of a case of bilateral paraovarian endometrioid cystic tumors of borderline malignancy and review of the literature.

Authors:  Rajeeva R Raju; William R Hart; David K Magnuson; Janet R Reid; Douglas G Rogers
Journal:  Mod Pathol       Date:  2002-02       Impact factor: 7.842

7.  Selumetinib in Children with Inoperable Plexiform Neurofibromas.

Authors:  Andrea M Gross; Pamela L Wolters; Eva Dombi; Andrea Baldwin; Patricia Whitcomb; Michael J Fisher; Brian Weiss; AeRang Kim; Miriam Bornhorst; Amish C Shah; Staci Martin; Marie C Roderick; Dominique C Pichard; Amanda Carbonell; Scott M Paul; Janet Therrien; Oxana Kapustina; Kara Heisey; D Wade Clapp; Chi Zhang; Cody J Peer; William D Figg; Malcolm Smith; John Glod; Jaishri O Blakeley; Seth M Steinberg; David J Venzon; L Austin Doyle; Brigitte C Widemann
Journal:  N Engl J Med       Date:  2020-03-18       Impact factor: 91.245

8.  Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors.

Authors:  Lydia W T Cheung; Shuangxing Yu; Dong Zhang; Jie Li; Patrick K S Ng; Nattapon Panupinthu; Shreya Mitra; Zhenlin Ju; Qinghua Yu; Han Liang; David H Hawke; Yiling Lu; Russell R Broaddus; Gordon B Mills
Journal:  Cancer Cell       Date:  2014-10-02       Impact factor: 31.743

9.  Cancer risks associated with the germline MITF(E318K) variant.

Authors:  Samantha M Guhan; Mykyta Artomov; Shelley McCormick; Ching -Ni Njauw; Alexander J Stratigos; Kristen Shannon; Leif W Ellisen; Hensin Tsao
Journal:  Sci Rep       Date:  2020-10-13       Impact factor: 4.379

10.  Somatic PIK3R1 variation as a cause of vascular malformations and overgrowth.

Authors:  Catherine E Cottrell; Nicole R Bender; Michael T Zimmermann; Jonathan W Heusel; Meagan Corliss; Michael J Evenson; Vincent Magrini; Donald J Corsmeier; Matthew Avenarius; Jeffrey N Dudley; Jennifer J Johnston; Marjorie J Lindhurst; Katinka Vigh-Conrad; Olivia M T Davies; Carrie C Coughlin; Ilona J Frieden; Megha Tollefson; Andrea L Zaenglein; Heather Ciliberto; Laura L Tosi; Robert K Semple; Leslie G Biesecker; Beth A Drolet
Journal:  Genet Med       Date:  2021-05-26       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.